Atrophic gastritis (AG) is a common and possibly precancerous digestive tract disease. The development of drugs with the effect of preventing precancerous lesions draws the eyes of global researchers. Creative Biolabs has extensive experience in the development of therapeutic antibodies and cell-based therapy for autoimmune diseases. We are committed to helping you develop new drugs for AG.

Introduction to Atrophic Gastritis (AG)

AG is a chronic disorder characterized by the decrease or the disappearance of the oxyntic glands, which could be replaced by fibrosis, or most frequently by pseudo-pyloric or intestinal metaplasia (IM). The lack of gastric acid and intrinsic factor production could lead to malabsorption of micronutrients such as iron and vitamin B12 and consequent anaemia.

Human gastric biopsy showing gastric gland atrophy. Fig.1 Human gastric biopsy showing gastric gland atrophy. (Artem, 2017)

Treatment of AG

A study has shown that Qilianshupi decoction (QLSP) is effective in the treatment of chronic atrophic gastritis (CAG). Compared with the group treated with vitacoenzyme, QLSP can significantly improve the pathological changes. The clinical data showed that QLSP can inhibit the destruction of gastric mucosal epithelium by H. pylori and significantly control H. pylori infection.

Indirect studies also indicate the therapeutic effect of QLSP. The wild-type p53 gene is a tumor suppressor gene. When p53 gene mutation occurs, uncontrolled regulation of cell cycle mediated by p53, which led to the disorder of DNA molecular program, genetic instability, and polyploid, the malignant proliferation of cells. There was no mutant p53 expression in normal gastric mucosal cells. However, during the process of chronic atrophic gastritis to intestinal metaplasia and dysplasia, we can see mutant p53 expression increasing. After QLSP treatment, mutant P53 protein expression decreased, which can confirm that QLSP significantly inhibited the intestinal metaplasia of CAG.

Flowchart of molecular mechanism analysis of QLSP for chronic atrophic gastritis. Fig.2 Flowchart of molecular mechanism analysis of QLSP for chronic atrophic gastritis. (Yameng, 2019)

Custom Services for Atrophic Gastritis Drug Development

Creative Biolabs is a service-oriented company that provides unique services in therapeutic antibody and cell therapy. Our experts have more than ten years of experience in drug research and development. From project design to formulation optimization, we have a wide range of technology platforms and a variety of equipment to meet the needs of customers. We explore the truth with our customers and our services which includes but not limited to:

  • Monoclonal Antibody Development for AG
  • Bispecific Antibody Development for AG
  • Cell-based Therapy for AG

With first-class technology and operation management, Creative Biolabs is determined to customize the most effective research and development program for global customers. Effective promotion of AG drug research and development is our common goal. If you want to enjoy the highest quality AG drug development services, please ask an expert for a specific consultation on your project.


  1. Artem, M.; et al. Autoimmune atrophic gastritis: current perspectives. Clinical & Experimental Gastroenterology. 2017, 10:19-27.
  2. Yameng, Zhang.; et al. Screening and Identification of Molecular Targets Involved in Preventing Gastric Precancerous Lesions in Chronic Atrophic Gastritis by Qilianshupi Decoction. Evidence-based complementary and alternative medicine : eCAM. 2019, 2019: 5804710-5804710.

For Research Use Only | Not For Clinical Use

Online Inquiry

Autoimmune Diseases

We are dedicated to advancing and facilitating your drug development against autoimmune diseases Contact us USA
  • Location:
  • Call:
  • Fax:
  • Email:
  • Location:
  • Call:
  • Email:
  • Location:
  • Call:
  • Email:

Autoimmune Diseases,Drug Development for
Autoimmune Diseases

Creative Biolabs is a world-leading CRO that is skilled in developing novel therapies,
especially in antibody and cell therapy for autoimmune diseases.

Copyright © 2024 Creative Biolabs. All Rights Reserved.